Intratumoral IL17-producing cells infiltration correlate with antitumor immune contexture and improved response to adjuvant chemotherapy in gastric cancer. (15th November 2018)
- Record Type:
- Journal Article
- Title:
- Intratumoral IL17-producing cells infiltration correlate with antitumor immune contexture and improved response to adjuvant chemotherapy in gastric cancer. (15th November 2018)
- Main Title:
- Intratumoral IL17-producing cells infiltration correlate with antitumor immune contexture and improved response to adjuvant chemotherapy in gastric cancer
- Authors:
- Wang, J T
Li, H
Zhang, H
Chen, Y F
Cao, Y F
Li, R C
Lin, C
Wei, Y C
Xiang, X N
Fang, H J
Zhang, H Y
Gu, Y
Liu, X
Zhou, R J
Liu, H
He, H Y
Zhang, W J
Shen, Z B
Qin, J
Xu, J J - Abstract:
- Abstract: Background: Tumor IL17-producing (IL17A + ) cells infiltration has different prognostic values among various cancers. The objective of this study was to assess the effect of IL17A + cells in gastric cancer. Patients and methods: The study included two patient cohorts, the Cancer Genome Atlas cohort ( TCGA, n = 351) and the Zhongshan Hospital cohort ( ZSHC, n = 458). The TCGA and ZSHC were used for mRNA-related and cells infiltration-related analyses, respectively. The roles of IL17A mRNA and IL17A + cells in overall survival (OS), response to adjuvant chemotherapy (ACT), and immune contexture were evaluated. Another independent cohort was included to identify the correlation between mRNA of IL17A and IL17A + cells infiltration (the preliminary Zhongshan Hospital cohort, PZSHC, n = 21). Results: The infiltration of IL17A + cells was positively correlated with the expression of IL17A mRNA (Spearman's ρ = 0.811; P < 0.001). High IL17A mRNA expression and intratumoral IL17A + cells were correlated with improved OS and remained to be significant after adjusted for confounders. Patients with TNM II/III disease whose tumor present higher intratumoral IL17A + cells or lower peritumoral IL17A + cells can benefit more from ACT. Elevated IL17A mRNA expression and increased intratumoral IL17A + cells infiltration was associated with more antitumor mast cells and nature killer cells infiltration and less pro-tumor M2 macrophages infiltration. High IL17A mRNAAbstract: Background: Tumor IL17-producing (IL17A + ) cells infiltration has different prognostic values among various cancers. The objective of this study was to assess the effect of IL17A + cells in gastric cancer. Patients and methods: The study included two patient cohorts, the Cancer Genome Atlas cohort ( TCGA, n = 351) and the Zhongshan Hospital cohort ( ZSHC, n = 458). The TCGA and ZSHC were used for mRNA-related and cells infiltration-related analyses, respectively. The roles of IL17A mRNA and IL17A + cells in overall survival (OS), response to adjuvant chemotherapy (ACT), and immune contexture were evaluated. Another independent cohort was included to identify the correlation between mRNA of IL17A and IL17A + cells infiltration (the preliminary Zhongshan Hospital cohort, PZSHC, n = 21). Results: The infiltration of IL17A + cells was positively correlated with the expression of IL17A mRNA (Spearman's ρ = 0.811; P < 0.001). High IL17A mRNA expression and intratumoral IL17A + cells were correlated with improved OS and remained to be significant after adjusted for confounders. Patients with TNM II/III disease whose tumor present higher intratumoral IL17A + cells or lower peritumoral IL17A + cells can benefit more from ACT. Elevated IL17A mRNA expression and increased intratumoral IL17A + cells infiltration was associated with more antitumor mast cells and nature killer cells infiltration and less pro-tumor M2 macrophages infiltration. High IL17A mRNA expression represented a Th17 cells signature and immune response process and was correlated with increased cytotoxic GZMA, GZMB, IFNG, PRF1, and TNFSF11 expression. Conclusions: IL17A mRNA expression and intratumoral IL17A + cells infiltration were correlated with antitumor immune contexture. IL17A + cells infiltration could be used as an independent prognostic biomarker for OS and predictive biomarker for superior response to ACT, and further prospective validation needs to be conducted. … (more)
- Is Part Of:
- Annals of oncology. Volume 30:Number 2(2019)
- Journal:
- Annals of oncology
- Issue:
- Volume 30:Number 2(2019)
- Issue Display:
- Volume 30, Issue 2 (2019)
- Year:
- 2019
- Volume:
- 30
- Issue:
- 2
- Issue Sort Value:
- 2019-0030-0002-0000
- Page Start:
- 266
- Page End:
- 273
- Publication Date:
- 2018-11-15
- Subjects:
- IL17-producing cells -- immune contexture -- prognosis -- adjuvant chemotherapy -- gastric cancer
Oncology -- Periodicals
616.992 - Journal URLs:
- https://www.journals.elsevier.com/annals-of-oncology ↗
http://ukcatalogue.oup.com/ ↗ - DOI:
- 10.1093/annonc/mdy505 ↗
- Languages:
- English
- ISSNs:
- 0923-7534
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 1043.320000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 11987.xml